China Large Volume Parenteral (LVP) Industry Report, 2013-2015
  • Nov./2013
  • Hard Copy
  • USD $1,900
  • Pages:65
  • Single User License
    (PDF Unprintable)       
  • USD $1,800
  • Code: ZYM050
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,800
  • Hard Copy + Single User License
  • USD $2,100
      
Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%.

Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for amino acids and fat emulsion dual-chamber bags, amino acids fat emulsion and glucose three-cavity all-in-one parenteral nutrition injections, hydroxyethyl starch and unique traditional Chinese medicine injection is quite strong.

Compared to Europe and other developed countries, the concentration degree of Chinese LVP market is still lower. At present, 200 ones of 400 qualified Chinese LVP enterprises run business soundly. By output, the top 10 Chinese companies contribute about 65%; in terms of sales revenue, they devote about 40 %.

Like other chemical preparation segments, Chinese high-end LVP market is still dominated by foreign pharmaceutical companies such as Japan Otsuka, Germany Fresenius Kabi, and USA Baxter.

20130295.png

Take fat emulsion products for example. Fat emulsion is imported by China frequently as a blood and hematopoietic system drug in recent years, with its import volume having been at the high level of typical urban hospitals in 22 Chinese cities for consecutive years. Particularly, the procurement value of moderate and long-chain fat emulsion imported by Chinese typical hospitals hit RMB354million. In China, fat emulsion injection suppliers include Kelun Pharma, Sino-Swed Pharmaceutical Corp, Ltd. (under Fresenius Kabi) and Guangzhou Baxter Qiaoguang (under Baxter) with the respective output of 14.19 million bottles/bags, 8.1 million bottles / bags (including medium/long-chain fat emulsion) and 5.69 million bottles/bags (medium/long-chain fat emulsion) in 2012.

The report highlights the followings:

20120114.gifStatus quo, competition patterns, product structure, regional distribution and development forecast of Chinese LVP market;
20120114.gifStatus quo and competition patterns of fluid balance injection, therapeutic injection, nutrition injection, injection for blood volume expansion and peritoneal dialysis fluid injection and other market segments;
20120114.gifOperation, LVP business and prospects of 10 companies including Kelun Pharma, China Resources Double-Crane, Fengyuan Pharmaceutical, Huaren Pharmaceutical, Southwest Pharmaceutical and Lijun International Pharmaceutical.
1 Overview of LVP
1.1 Definition and Classification
1.2 Industry Chain

2 Overview of China LVP Industry Development
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution

3 Chinese LVP Market Segments
3.1 Injection for Body Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion 
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysate

4 Main Companies
4.1 Kelun Pharma 
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 Gross Margin 
4.1.5 Clients and Suppliers 
4.1.6 R & D and Investment
4.1.7 LVP Business 
4.1.8 Development Forecast 
4.2 China Resources Double-Crane 
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin 
4.2.5 Major Clients 
4.2.6 LVP Business 
4.2.7 Development Forecast 
4.3 Fengyuan Pharmaceutical  
4.3.1 Profile 
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin 
4.3.5 Clients and Suppliers 
4.3.6 LVP Business 
4.3.7 Development Forecast 
4.4 Huaren Pharmaceutical
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Gross Margin 
4.4.5 Clients and Suppliers 
4.4.6 R & D and Investment
4.4.7 Development Forecast 
4.5 Southwest Pharmaceutical 
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Major Clients 
4.5.6 LVP Business 
4.5.7 Development Forecast 
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation 
4.6.3 Shijiazhuang No.4 Pharmaceutical 
4.7 Jinjian Cereals
4.7.1 Profile
4.7.2 Operation
4.7.3 Jinjiang Phamaceutical
4.8 Other Companies
4.8.1 Qingzhou Yaowang Medicine
4.8.2 Jilin Dubang Pharmaceutical
4.8.3 Shandong Lukang Cisen Pharmaceutical
4.8.4 China Otsuka Pharmaceutical

5 China LVP Industry Summary and Development Prediction
5.1 Market Size to Ascend but Capacity Growth to Slow Down
5.2 Industry Concentration to Improve and Large Players with Obivious Competitive Edges
5.3 Product Structure to Upgrade and New LVP Products Development to be Trend
Classification, Application and Commodities of LVP (by Clinical Use)
LVP Industry Chain
LVP Output and YoY Growth Rate in China, 2008-2012
Competition Patterns of Chinese LVP Companies (by Output), 2012
Competition Patterns of Chinese LVP Companies (by Sales Volume or Value), 2011 
Top 10 LVP Varieties and Output in China, 2011-2012
Proportion of LVP Sales Volume or Value (by Product) in China, 2011
Sales Volume / Value Growth Rate of Major LVP Varieties in China, 2007-2011
Regional Distribution of LVP (by Output) in China, 2011-2012 
Major Varieties and Output of Fluid Balance Injection in China, 2010-2012
Major Varieties and Output of Therapeutic Injection in China, 2010-2012
Major Mannitol Injection Enterprises and Their Output in China, 2012
Bid Prices of Some National Essential Drugs in China, 2013
Major Fructose (10%, 500ml) Injection Enterprises and Their Output in China, 2011-2012
Major Glycerol and Fructose Sodium Chloride Injection (CO 250ml) Enterprises and Their Output in China, 2011-2012
Amino Acid Injection Varieties and Major Enterprises and Their Output in China, 2012
Major N (2)-L-propylamine acyl-L-glutamyl Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported N (2)-L-propylamine acyl-L-glutamyl of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Fat Emulsion Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Fat Emulsion Injection of Typical Hospitals in 22 Chinese Cities, 2010-2012
Major Dextran Injection Enterprises and Their Output in China, 2012
Major Hydroxyethyl Starch Injection Enterprises and Their Output in China, 2012
Purchase Costs of Imported Hydroxyethyl Starch of Typical Hospitals in 22 Chinese Cities, 2010-2012
Purchase Costs of Peritoneal Dialysate of Typical Hospitals in 22 Chinese Cities, 2010-2012   
Major Peritoneal Dialysate Enterprises and Their Output in China, 2012
Revenue and Profit of Kelun Pharma, 2008-2013
Revenue of Kelun Pharma (by Product), 2008-2013
Revenue of Kelun (by Region), 2008-2013
Gross Margin of Kelun Pharma (by Product), 2008-2013 
Kelun Pharma’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Kelun Pharma’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2012
R & D Costs and % of Total Revenue of Kelun Pharma, 2011-2013   
LVP Output, Sales Volume and Inventory of Kelun Pharma, 2011-2012  
LVP Revenue and Gross Margin of Kelun Pharma, 2008-2013 
LVP Revenue of Kelun (by Product), 2008-2013
Revenue and Net Income of Kelun Pharma, 2012-2015E
Revenue and Profit of China Resources Double-Crane, 2008-2013
Revenue of China Resources Double-Crane (by Product), 2008-2013
Revenue of China Resources Double-Crane (by Region), 2008-2013
Gross Margin of China Resources Double-Crane (by Product), 2008-2013
China Resources Double-Crane’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of China Resources Double-Crane, H1 2013
Injection Output of China Resources Double-Crane, 2010-2012
Injection Revenue and Gross Margin of China Resources Double-Crane, 2008-2013
Progress of Online Projects of China Resources Double-Crane, by Jun 2013
Revenue and Net Income of China Resources Double-Crane, 2012-2015E
Revenue and Net Income of Fengyuan Pharmaceutical, 2008-2013
Revenue of Fengyuan Pharmaceutical (by Product), 2008-2013
Revenue of Fengyuan Pharmaceutical (by Region), 2008-2013
Gross Margin of Fengyuan Pharmaceutical (by Product), 2008-2013 
Fengyuan Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Fengyuan Pharmaceutical, 2012-H1 2013
Fengyuan Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013 
Name List and Procurement of Top 5 Suppliers of Fengyuan Pharmaceutical, 2012
LVP Output of Fengyuan Pharmaceutical, 2010-2012   
Revenue and Net Income of Fengyuan Pharmaceutical , 2012-2015E
LVP Output, Sales Volume and Inventory of Huaren Pharmaceutical, 2011-2012
Revenue and Net Income of Huaren Pharmaceutical, 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Revenue of Huaren Pharmaceutical (by Region), 2008-2013
Revenue of Huaren Pharmaceutical (by Product), 2008-2013
Huaren Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2013
Name List and Procurement of Top 5 Suppliers of Huaren Pharmaceutical, H1 2013
Huaren Pharmaceutical’s Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2013
Name List and Revenue Contribution of Top 5 Clients of Huaren Pharmaceutical, H1 2013
R & D Costs and % of Total Revenue of Huaren Pharmaceutical, 2008-2013
Progress of Major R & D Projects of Huaren Pharmaceutical, by 2013
Revenue and Net Income of Huaren Pharmaceutical , 2012-2015E
Revenue and Net Income of Southwest Pharmaceutical, 2008-2013
Operating Revenue of Southwest Pharmaceutical (by Product), 2008-2013
Revenue of Southwest Pharmaceutical (by Region), 2008-2013
Gross Margin of Southwest Pharmaceutical (by Product), 2008-2013 
Southwest Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2008-2012
Name List and Revenue Contribution of Top 5 Clients of Southwest Pharmaceutical, 2012
LVP Revenue and Gross Margin of Southwest Pharmaceutical , 2008-2013 
Injection Output of Southwest Pharmaceutical, 2010-2012
Revenue and Net Income of Southwest Pharmaceutical, 2012-2015E
Revenue of Lijun International Pharmaceutical (Holding), 2011-2013
Revenue of Shijiazhuang No.4 Pharmaceutical (by Product), 2011-2013
Gross Margin of Shijiazhuang No.4 Pharmaceutical , 2008-2013
Revenue and Net Income of Jin Jian Pharmaceutical, 2008-2013
LVP Output of Jin Jian Pharmaceutical, 2010-2012
Revenue and Gross Margin of Jin Jian Pharmaceutical, 2008-2013 
Injection Output of Qingzhou Yaowang Medicine, 2010-2012
Injection Products and Prices of Qingzhou Yaowang Medicine
LVP Output of Dubang Pharmaceutical, 2010-2012
LVP Output of Shandong Lukang Cisen Pharmaceutical, 2010-2012
LVP Output of China Otsuka Pharmaceutical, 2010-2012
Major Injection Products of China Otsuka Pharmaceutical
Injection Output and Demand in China, 2012-2015E
Output of Top 10 Injection Producers in China, 2011-2012
LVP Revenue of Major Chinese Producers, 2008-2012
LVP Gross Margin of Major Chinese Producers, 2008-2013
Proportion of LVP Sales Volume or Value (by Product) in China, 2015E

China Pharmaceutical Distribution Industry Report, 2019-2025

China’s pharmaceutical distribution industry has sustained steady growth over the years. In 2018, the market was worth RMB2,194.5 billion, a 9.6% rise from RMB2,001.6 billion (up by 8.4% YoY) in 2017,...

China Pharmaceutical Packaging Industry Report, 2019-2025

Being incentivized by the burgeoning pharmaceuticals industry, Chinese pharmaceutical packaging market size sustained growth rates of around 10% in recent years, and outstripped RMB100 billion in 2018...

China Blood Product Industry Report, 2018-2022

The blood product industry in China develops under stimulation of industry policies and downstream demand. The country recorded total lot release volume of 64.11 million bottles of blood products in 2...

China Pharmaceutical Distribution Industry Report, 2017-2021

The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit...

China Blood Product Industry Report, 2017-2021

China’s blood product market size mushroomed in 2016 under the impetus of liberalization of limited-price policy, price rises in varying degrees and lot release volume growth for blood products in 201...

China Pharmaceutical Packaging Industry Report, 2016-2021

Under the impetus of the fast-growing downstream pharmaceutical industry, Chinese pharmaceutical packaging market size increased year by year at the CAGR of 11.2% during 2010-2016. From 2017 to 2021, ...

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Ch...

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号